Acquisition of Tetraphase Pharmaceuticals, Inc. Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended
	Jul. 28, 2020	Mar. 31, 2021
Business Acquisition [Line Items]
Inventory fair value step up adjustment		$ 850
Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Business acquisition, date of acquisition agreement	Jun. 24, 2020
Upfront cash for acquisition	$ 42,990
Future cash payments	16,000
Additional aggregate payments	16,000
Business acquisition, description		The holders of the CVRs are entitled to receive potential future cash payments of up to $16 million in the aggregate upon the achievement of certain net sales of XERAVA in the U.S. as follows: (i) $2.5 million if 2021 XERAVA U.S. net sales are at least $20 million; (ii) $4.5 million if XERAVA U.S. net sales are at least $35 million during any calendar year ending on or prior to December 31, 2024; and (iii) $9 million if XERAVA U.S. net sales are at least $55 million during any calendar year ending on or prior to December 31, 2024.
Estimated fair value of assets acquired	54,700
Estimated fair value of liabilities assumed	9,100
Loss recorded in other (expense) income resulting from the change in fair value of CVRs		$ 500
Inventory fair value step up adjustment	$ 3,300
Weighted-average Years	10 years
Tetraphase Pharmaceuticals, Inc. | Cost of Product Sales
Business Acquisition [Line Items]
Inventory fair value step up adjustment		$ 900
Agreement 1 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	$ 2,500
Net sales from related parties	20,000
Agreement 2 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	4,500
Net sales from related parties	35,000
Agreement 3 | Tetraphase Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Proceeds from businesses and interest in affiliates	9,000
Net sales from related parties	$ 55,000